FIELD: medicine.
SUBSTANCE: invention refers to medicine, namely to cardiology and pharmacology, and concerns correction of endothelial dysfunction. That is ensured by administering an activated potentiated form of vascular endothelial growth factor (VEGF) antibodies in an effective amount.
EFFECT: correction of endothelial dysfunction.
5 cl, 1 tbl, 1 ex
| Title | Year | Author | Number |
|---|---|---|---|
| THERAPEUTIC AGENT FOR ENDOTHELIAL DYSFUNCTION CORRECTION | 2011 |
|
RU2500424C2 |
| MEDICATION FOR CORRECTION OF ENDOTHELIAL DYSFUNCTION | 2011 |
|
RU2536228C2 |
| METHOD FOR ENDOTHELIAL DYSFUNCTION CORRECTION | 2011 |
|
RU2541166C2 |
| METHOD FOR ENDOTHELIAL DYSFUNCTION CORRECTION | 2011 |
|
RU2542403C2 |
| THERAPEUTIC AGENT FOR ENDOTHELIAL DYSFUNCTION CORRECTION | 2011 |
|
RU2543332C2 |
| THERAPEUTIC AGENT FOR ENDOTHELIAL DYSFUNCTION CORRECTION | 2011 |
|
RU2543331C2 |
| METHOD FOR CORRECTION OF ENDOTHELIAL DYSFUNCTION | 2011 |
|
RU2527689C2 |
| METHOD FOR CORRECTION OF ENDOTHELIAL DYSFUNCTION BY SOLUTION OF HOMOEOPATHIC DILUTIONS OF VASCULAR ENDOTHELIAL GROWTH FACTOR ANTIBODIES | 2011 |
|
RU2526151C2 |
| METHOD OF TREATING CHRONIC CARDIAC FAILURE AND PHARMACEUTICAL COMPOSITION FOR TREATING CHRONIC CARDIAC FAILURE | 2011 |
|
RU2523451C2 |
| METHOD FOR CORRECTION OF ENDOTHELIAL DYSFUNCTION BY SOLUTION OF HOMOEOPATHIC DILUTIONS OF INTERLEUKIN-1 ANTIBODIES | 2011 |
|
RU2526150C2 |
